6550--NTX Ventana Reagents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 17, has awarded a Firm-Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Roche Diagnostics Corporation for Ventana reagents and consumable supplies. This award, valued at $1,400,000.00, supports the North Texas Health Care System's Pathology & Laboratory Medicine Service.
Scope of Work
The contract covers the procurement of essential reagents and consumable supplies, including but not limited to DAB Detection reagent, Hematoxylin, various staining kits (e.g., Elastin Van Gieson Kit), antibodies (e.g., Confirm Anti-Thyroid Transcription Factor, Confirm Cytokeratin7 Rabbitmono, Antibody – KI 67), printer ribbons, and IHC ancillaries. These items are exclusively compatible with the government-owned Ventana BenchMark Ultra and Ventana HE600 systems. Supplies will be ordered on an as-needed basis.
Contract & Timeline
- Awardee: Roche Diagnostics Corporation (UEI JDMDFEZBYH36)
- Contract Type: Firm-Fixed-Price (FFP) Indefinite Delivery/Indefinite Quantity (IDIQ)
- Award Number: 36C25726D0065
- Award Amount: $1,400,000.00 (ceiling)
- Award Date: April 21, 2026
- Period of Performance: Five one-year ordering periods, from April 19, 2026, through April 18, 2031.
- Set-Aside: None (Sole Source)
- Product Service Code (PSC): 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits And Sets)
- NAICS Code: 325413 (In-Vitro Diagnostic Substance Manufacturing)
Justification & Evaluation
This acquisition was conducted as a sole source award under statutory authorities permitting other than full and open competition (41 U.S.C. 3304(a)(1) and FAR 6.302-1). The justification is based on the unique qualifications of Ventana Medical Systems, Inc. (a member of the Roche Group) as the exclusive manufacturer of the required reagents and supplies, which are indispensable for the operation of the VA's existing Ventana BenchMark Ultra and HE600 systems. Market research, including a Special Notice on SAM.gov from February 3-9, 2026, did not identify any other responsible sources capable of meeting these specific requirements.
Contact Information
For inquiries regarding this award, contact Susan Flores, Contract Specialist, at Susan.flores2@va.gov or (210) 694-6227.